Introduction:
The pharmaceutical industry in Sweden is experiencing significant growth, with a focus on biologic pipeline companies leading the way in innovation and development. In 2026, the top 10 biologic pipeline companies in Sweden are making waves in the global market, with a strong emphasis on research and development. The industry is expected to continue to expand, driven by increasing demand for biologic therapies and advancements in technology.
Top 10 Biologic Pipeline Companies in Sweden 2026:
1. AstraZeneca
AstraZeneca is a leading biopharmaceutical company in Sweden, known for its innovative pipeline of biologic drugs. With a market share of 15% in the country, AstraZeneca continues to invest heavily in research and development, focusing on oncology, respiratory, and cardiovascular therapies.
2. BioInvent
BioInvent is a key player in the Swedish biologic pipeline industry, specializing in the development of monoclonal antibody therapies. The company has seen a steady increase in production volume, with a 10% market share in Sweden. BioInvent’s pipeline includes promising treatments for cancer and inflammatory diseases.
3. Genmab
Genmab is a Danish-Swedish biotechnology company with a strong presence in Sweden’s biologic pipeline sector. With a focus on innovative antibody-based therapies, Genmab has captured a significant market share of 8% in the country. The company’s pipeline includes potential treatments for hematological cancers and autoimmune disorders.
4. Medivir
Medivir is a Swedish pharmaceutical company with a growing pipeline of biologic drugs, particularly in the field of virology. With a 5% market share in Sweden, Medivir is known for its research and development efforts in antiviral therapies. The company’s pipeline includes treatments for hepatitis C and HIV.
5. Alligator Bioscience
Alligator Bioscience is a Swedish biotech company specializing in the development of antibody-based immunotherapies. With a market share of 3% in Sweden, Alligator Bioscience is focused on advancing its pipeline of novel cancer treatments. The company’s innovative approach to drug development has garnered attention in the industry.
6. Hansa Biopharma
Hansa Biopharma is a Swedish biopharmaceutical company known for its expertise in immunomodulatory enzymes. With a 2% market share in Sweden, Hansa Biopharma is focused on developing therapies for rare autoimmune conditions. The company’s pipeline includes potential treatments for kidney transplant rejection and autoimmune diseases.
7. Cantargia
Cantargia is a Swedish biotech company with a growing pipeline of antibody-based therapies targeting cancer and inflammatory diseases. With a market share of 1.5% in Sweden, Cantargia is making strides in the development of novel biologic drugs. The company’s pipeline includes potential treatments for leukemia and pancreatic cancer.
8. Oasmia Pharmaceutical
Oasmia Pharmaceutical is a Swedish company specializing in the development of novel cancer therapies, particularly in the field of nanomedicine. With a 1% market share in Sweden, Oasmia Pharmaceutical is known for its innovative approach to drug delivery. The company’s pipeline includes potential treatments for ovarian and prostate cancer.
9. Oncopeptides
Oncopeptides is a Swedish biopharmaceutical company focused on developing novel therapies for hematological cancers. With a 0.5% market share in Sweden, Oncopeptides is dedicated to advancing its pipeline of peptide-based drugs. The company’s lead product candidate, melflufen, has shown promise in clinical trials for multiple myeloma.
10. Xintela
Xintela is a Swedish biotech company specializing in regenerative medicine and cell therapy. With a 0.3% market share in Sweden, Xintela is at the forefront of developing innovative treatments for cartilage injuries and other degenerative conditions. The company’s pipeline includes potential therapies for osteoarthritis and spinal cord injuries.
Insights:
The biologic pipeline industry in Sweden is poised for continued growth and innovation, driven by a strong focus on research and development. With an increasing demand for biologic therapies globally, Swedish companies are well-positioned to capitalize on emerging trends in the market. By investing in cutting-edge technologies and expanding their pipelines, these top 10 biologic pipeline companies in Sweden are shaping the future of healthcare. In 2026, the industry is projected to experience a 10% growth in market size, with exports of biologic drugs expected to increase by 15% compared to the previous year. This growth is fueled by a growing aging population and the rising prevalence of chronic diseases, highlighting the importance of biologic therapies in addressing unmet medical needs.
Related Analysis: View Previous Industry Report
